Redefining
the Future of
Early Cancer Detection:
Liquid Biopsy- CtDNA
At Telotech, an In-Vitro Diagnostics Lab, member of BioCreatrix. We are revolutionizing cancer detection and treatment through our pioneering liquid biopsy technologies. Our advanced genomic analysis platforms provide unparalleled insights into a patient's cancer, empowering earlier diagnosis, more personalized treatments, and improved outcomes.
​
Providing services for Local & International Oncologists, Medical Groups, Hospitals & Pharmaceutical Companies for target/immune drugs matching based on our capability of super deep NGS Sequencing of Tumour Driving genes somatic mutations based on Cell Free DNA.
1
Ultrasensitive ctDNA Analysis
The centerpiece of our liquid biopsy offering is our ultra-deep sequencing platform, which can detect cancer-derived circulating tumor DNA (ctDNA) with industry-leading 20,000x depth of coverage.
​
This unprecedented level of sensitivity allows us to identify even the rarest genetic alterations associated with cancer, including both germline and somatic mutations. By casting a wide net, our ctDNA analysis can uncover genetic markers that traditional tissue biopsies Immunohistochemistry (IHC) & Next- Generation Sequencing (NGS) often cannot fully capture.
2
Full-Spectrum Genomic Profiling
Alongside our ultrasensitive ctDNA detection, Telotech also provides comprehensive genomic profiling through our full-panel gene sequencing assays. Our panels interrogate a full array of genes known to be involved in cancer development, progression, relapse and druggable targets.
​
This holistic view of a patient's genetic landscape enables us to uncover the full spectrum of cancer-driving mutations - from well-known tumour driving gene hotspot mutations to more rare and emerging targets. With this rich genomic data, we can guide the selection of targeted therapies that are tailored to each individual's unique tumor profile.
3
Empowering Precision Oncology
By combining our liquid biopsy expertise with advanced bioinformatics and machine learning, Telotech is empowering a new era of precision oncology.
Our tests can:
​
- Detect cancer at the earliest stages, when interventions are most effective
- Identify actionable genomic targets to guide targeted therapy selection
- Monitor treatment response and detect emerging drug resistance
- Uncover novel biomarkers to accelerate drug development
Get in Touch
Experience the transformative potential of liquid biopsy with Telotech. Contact us today to learn more about our CtDNA liquid biopsy and how they can benefit your clinical practice or research program.